DAIICHI SANKYO acquires osteoporosis medication EVISTA® from Lilly

DAIICHI SANKYO CompanyThe Japanese pharmaceutical company DAIICHI SANKYO Group has purchased the European rights to the osteoporosis medication EVISTA® from the U.S. Company Eli Lilly and Company. In the process, the company is planning to gain additional sales volume of approximately €80 million.

"By purchasing these rights, we are pressing ahead with our expansion strategy in Europe and have taken another major step toward our goal of achieving at least €1 billion in sales by no later than 2011," said Reinhard Bauer, CEO of DAIICHI SANKYO EUROPE GmbH. But, Bauer noted this was only an interim objective. "By 2015, we intend to be one of the leading research-focused pharmaceutical companies in Europe," he added.

In 2006, the marketing and distribution rights to EVISTA® in six European countries, including Germany, Italy, Belgium, Netherlands, Switzerland and Austria were granted to DAIICHI SANKYO. The latest agreement covers the remaining countries in Europe, with the exception of Greece, where Lilly will continue to market the product with its joint venture company Pharmaserve. The recent agreement is subject to the approval of the competent antitrust authorities.

The agreement represents an expansion of the partnership between DAIICHI SANKYO and Eli Lilly and Company. Both companies are already working jointly on Prasugrel, an oral antiplatelet agent originally developed by DAIICHI SANKYO.

About DAIICHI SANKYO Company, Limited
DAIICHI SANKYO Company, Limited, established in 2005 after the merger of two leading century-old Japanese pharmaceutical companies, is a global pharmaceutical innovator, continuously generating innovative drugs that enrich the quality of life for patients around the world. The company uses its cumulative knowledge and expertise in the fields of cardiovascular disease, cancer, metabolic disorders, and infection as a foundation for developing an abundant product lineup and R&D pipeline. For more information, visit www.daiichi-sankyo.eu.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Pfizer receives FDA approval for SUTENT® (sunitini…

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]